Invention Grant
- Patent Title: High affinity antibody antagonists of interleukin-13 receptor alpha 1
-
Application No.: US15160166Application Date: 2016-05-20
-
Publication No.: US09777062B2Publication Date: 2017-10-03
- Inventor: Andrew Donald Nash , Manuel Baca , Louis Jerry Fabri , Dennis Zaller , William R. Strohl , Zhiqiang An
- Applicant: CSL Limited
- Applicant Address: AU Victoria
- Assignee: CSL Limited
- Current Assignee: CSL Limited
- Current Assignee Address: AU Victoria
- Agency: Licata & Tyrrell P.C.
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C07K16/28 ; C12P21/00

Abstract:
High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
Public/Granted literature
- US20160362497A1 HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1 Public/Granted day:2016-12-15
Information query